ID   GNPTA_HUMAN             Reviewed;        1256 AA.
AC   Q3T906; A2RRQ9; Q3ZQK2; Q6IPW5; Q86TQ2; Q96N13; Q9ULL2;
DT   07-MAR-2006, integrated into UniProtKB/Swiss-Prot.
DT   11-OCT-2005, sequence version 1.
DT   10-MAY-2017, entry version 116.
DE   RecName: Full=N-acetylglucosamine-1-phosphotransferase subunits alpha/beta;
DE            EC=2.7.8.17 {ECO:0000269|PubMed:19955174};
DE   AltName: Full=GlcNAc-1-phosphotransferase subunits alpha/beta;
DE   AltName: Full=Stealth protein GNPTAB;
DE   AltName: Full=UDP-N-acetylglucosamine-1-phosphotransferase subunits alpha/beta;
DE   Contains:
DE     RecName: Full=N-acetylglucosamine-1-phosphotransferase subunit alpha;
DE   Contains:
DE     RecName: Full=N-acetylglucosamine-1-phosphotransferase subunit beta;
DE   Flags: Precursor;
GN   Name=GNPTAB; Synonyms=GNPTA, KIAA1208;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), SUBCELLULAR LOCATION, AND
RP   INVOLVEMENT IN MLII.
RX   PubMed=16200072; DOI=10.1038/nm1305;
RA   Tiede S., Storch S., Luebke T., Henrissat B., Bargal R.,
RA   Raas-Rothschild A., Braulke T.;
RT   "Mucolipidosis II is caused by mutations in GNPTA encoding the
RT   alpha/beta GlcNAc-1-phosphotransferase.";
RL   Nat. Med. 11:1109-1112(2005).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), TISSUE SPECIFICITY, AND
RP   SUBCELLULAR LOCATION.
RX   PubMed=16120602; DOI=10.1074/jbc.M509008200;
RA   Kudo M., Bao M., D'Souza A., Ying F., Pan H., Roe B.A., Canfield W.M.;
RT   "The alpha- and beta-subunits of the human UDP-N-
RT   acetylglucosamine:lysosomal enzyme N-acetylglucosamine-1-
RT   phosphotransferase are encoded by a single cDNA.";
RL   J. Biol. Chem. 280:36141-36149(2005).
RN   [3]
RP   ERRATUM.
RA   Kudo M., Bao M., D'Souza A., Ying F., Pan H., Roe B.A., Canfield W.M.;
RL   J. Biol. Chem. 280:42476-42476(2005).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2).
RC   TISSUE=Liver;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 1-847 (ISOFORM 1).
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 307-1256 (ISOFORM 1).
RC   TISSUE=Brain;
RX   PubMed=10574462; DOI=10.1093/dnares/6.5.337;
RA   Nagase T., Ishikawa K., Kikuno R., Hirosawa M., Nomura N., Ohara O.;
RT   "Prediction of the coding sequences of unidentified human genes. XV.
RT   The complete sequences of 100 new cDNA clones from brain which code
RT   for large proteins in vitro.";
RL   DNA Res. 6:337-345(1999).
RN   [7]
RP   SEQUENCE REVISION.
RX   PubMed=12168954; DOI=10.1093/dnares/9.3.99;
RA   Nakajima D., Okazaki N., Yamakawa H., Kikuno R., Ohara O., Nagase T.;
RT   "Construction of expression-ready cDNA clones for KIAA genes: manual
RT   curation of 330 KIAA cDNA clones.";
RL   DNA Res. 9:99-106(2002).
RN   [8]
RP   IDENTIFICATION AS A STEALTH PROTEIN, AND PUTATIVE FUNCTION.
RX   PubMed=16299590; DOI=10.1371/journal.pcbi.0010063;
RA   Sperisen P., Schmid C.D., Bucher P., Zilian O.;
RT   "Stealth proteins: in silico identification of a novel protein family
RT   rendering bacterial pathogens invisible to host immune defense.";
RL   PLoS Comput. Biol. 1:492-499(2005).
RN   [9]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-699.
RC   TISSUE=Liver;
RX   PubMed=19159218; DOI=10.1021/pr8008012;
RA   Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.;
RT   "Glycoproteomics analysis of human liver tissue by combination of
RT   multiple enzyme digestion and hydrazide chemistry.";
RL   J. Proteome Res. 8:651-661(2009).
RN   [10]
RP   FUNCTION, CATALYTIC ACTIVITY, AND SUBUNIT.
RX   PubMed=19955174; DOI=10.1074/jbc.M109.068650;
RA   Qian Y., Lee I., Lee W.S., Qian M., Kudo M., Canfield W.M., Lobel P.,
RA   Kornfeld S.;
RT   "Functions of the alpha, beta, and gamma subunits of UDP-
RT   GlcNAc:lysosomal enzyme N-acetylglucosamine-1-phosphotransferase.";
RL   J. Biol. Chem. 285:3360-3370(2010).
RN   [11]
RP   PROTEOLYTIC PROCESSING, SUBCELLULAR LOCATION, GLYCOSYLATION, AND
RP   MUTAGENESIS OF ARG-925; LEU-927 AND LYS-928.
RX   PubMed=21719679; DOI=10.1126/science.1205677;
RA   Marschner K., Kollmann K., Schweizer M., Braulke T., Pohl S.;
RT   "A key enzyme in the biogenesis of lysosomes is a protease that
RT   regulates cholesterol metabolism.";
RL   Science 333:87-90(2011).
RN   [12]
RP   INVOLVEMENT IN MLII.
RX   PubMed=23773965; DOI=10.1016/j.ygeno.2013.06.001;
RA   Yang Y., Wu J., Liu H., Chen X., Wang Y., Zhao M., He X.;
RT   "Two homozygous nonsense mutations of GNPTAB gene in two Chinese
RT   families with mucolipidosis II alpha/beta using targeted next-
RT   generation sequencing.";
RL   Genomics 102:169-173(2013).
RN   [13]
RP   CHARACTERIZATION OF VARIANTS MLIIIA GLN-4 AND TYR-15.
RX   PubMed=24550498; DOI=10.1073/pnas.1401417111;
RA   van Meel E., Qian Y., Kornfeld S.A.;
RT   "Mislocalization of phosphotransferase as a cause of mucolipidosis III
RT   alphabeta.";
RL   Proc. Natl. Acad. Sci. U.S.A. 111:3532-3537(2014).
RN   [14]
RP   CHARACTERIZATION OF VARIANTS MLII LEU-81; ASP-182; PRO-205; LEU-334;
RP   LEU-348; LEU-374; ASN-732; ARG-928; VAL-955; CYS-986; PRO-1001;
RP   VAL-1054 AND MET-1236, CHARACTERIZATION OF VARIANTS MLIIIA GLN-4;
RP   TYR-15; VAL-190; GLN-334; PHE-399; THR-403; ALA-407; TYR-442; GLY-461;
RP   SER-468; TYR-505; PRO-587; PRO-926; TYR-956; GLY-1018 AND SER-1153,
RP   AND CHARACTERIZATION OF VARIANTS ARG-523; THR-592 AND TRP-785.
RX   PubMed=25505245; DOI=10.1074/jbc.M114.612507;
RA   Qian Y., van Meel E., Flanagan-Steet H., Yox A., Steet R.,
RA   Kornfeld S.;
RT   "Analysis of mucolipidosis II/III GNPTAB missense mutations identifies
RT   domains of UDP-GlcNAc:lysosomal enzyme GlcNAc-1-phosphotransferase
RT   involved in catalytic function and lysosomal enzyme recognition.";
RL   J. Biol. Chem. 290:3045-3056(2015).
RN   [15]
RP   VARIANT MLIIIA ALA-407, AND VARIANT GLY-662.
RX   PubMed=16094673; DOI=10.1002/ajmg.a.30868;
RA   Tiede S., Muschol N., Reutter G., Cantz M., Ullrich K., Braulke T.;
RT   "Missense mutations in N-acetylglucosamine-1-phosphotransferase
RT   alpha/beta subunit gene in a patient with mucolipidosis III and a mild
RT   clinical phenotype.";
RL   Am. J. Med. Genet. A 137:235-240(2005).
RN   [16]
RP   VARIANT MLIIIA GLN-4.
RX   PubMed=16465621; DOI=10.1086/500849;
RA   Kudo M., Brem M.S., Canfield W.M.;
RT   "Mucolipidosis II (I-cell disease) and mucolipidosis IIIA (classical
RT   pseudo-Hurler polydystrophy) are caused by mutations in the GlcNAc-
RT   phosphotransferase alpha/beta-subunits precursor gene.";
RL   Am. J. Hum. Genet. 78:451-463(2006).
RN   [17]
RP   VARIANT MLII MET-1236.
RX   PubMed=16835905; DOI=10.1002/humu.9443;
RA   Tiede S., Cantz M., Spranger J., Braulke T.;
RT   "Missense mutation in the N-acetylglucosamine-1-phosphotransferase
RT   gene (GNPTA) in a patient with mucolipidosis II induces changes in the
RT   size and cellular distribution of GNPTG.";
RL   Hum. Mutat. 27:830-831(2006).
RN   [18]
RP   VARIANT MLIIIA PHE-399.
RX   PubMed=16630736; DOI=10.1016/j.ymgme.2006.03.003;
RA   Bargal R., Zeigler M., Abu-Libdeh B., Zuri V., Mandel H.,
RA   Ben Neriah Z., Stewart F., Elcioglu N., Hindi T., Le Merrer M.,
RA   Bach G., Raas-Rothschild A.;
RT   "When Mucolipidosis III meets Mucolipidosis II: GNPTA gene mutations
RT   in 24 patients.";
RL   Mol. Genet. Metab. 88:359-363(2006).
RN   [19]
RP   VARIANT MLIIIA PRO-587.
RX   PubMed=17034777; DOI=10.1016/j.cca.2006.09.004;
RA   Lam C.W., Yan M.S., Li C.K., Lau K.C., Tong S.F., Tang H.Y.;
RT   "DNA-based diagnosis of mucolipidosis type IIIA and
RT   mucopolysacchariodisis type VI in a Chinese family: a chance of 1 in
RT   7.6 trillion.";
RL   Clin. Chim. Acta 376:250-252(2007).
RN   [20]
RP   VARIANTS MLII ASP-182; PRO-205; ASN-732; ARG-928; VAL-955 AND
RP   VAL-1054, VARIANT MLIIIA GLN-4, AND CHARACTERIZATION OF VARIANT MLIIIA
RP   GLN-4.
RX   PubMed=19938078; DOI=10.1002/ajmg.a.33134;
RA   Zarghooni M., Dittakavi S.S.;
RT   "Molecular analysis of cell lines from patients with mucolipidosis II
RT   and mucolipidosis III.";
RL   Am. J. Med. Genet. A 149A:2753-2761(2009).
RN   [21]
RP   VARIANTS MLIIIA THR-403; TYR-442; GLY-461 AND PRO-926, AND VARIANT
RP   MLII PRO-1001.
RX   PubMed=19634183; DOI=10.1002/humu.21099;
RA   Tappino B., Chuzhanova N.A., Regis S., Dardis A., Corsolini F.,
RA   Stroppiano M., Tonoli E., Beccari T., Rosano C., Mucha J., Blanco M.,
RA   Szlago M., Di Rocco M., Cooper D.N., Filocamo M.;
RT   "Molecular characterization of 22 novel UDP-N-acetylglucosamine-1-
RT   phosphate transferase alpha- and beta-subunit (GNPTAB) gene mutations
RT   causing mucolipidosis types IIalpha/beta and IIIalpha/beta in 46
RT   patients.";
RL   Hum. Mutat. 30:E956-E973(2009).
RN   [22]
RP   VARIANTS MLII LEU-334 AND LEU-374, AND VARIANTS MLIIIA LEU-374;
RP   TYR-956 AND SER-1153.
RX   PubMed=19197337; DOI=10.1038/jhg.2009.3;
RA   Otomo T., Muramatsu T., Yorifuji T., Okuyama T., Nakabayashi H.,
RA   Fukao T., Ohura T., Yoshino M., Tanaka A., Okamoto N., Inui K.,
RA   Ozono K., Sakai N.;
RT   "Mucolipidosis II and III alpha/beta: mutation analysis of 40 Japanese
RT   patients showed genotype-phenotype correlation.";
RL   J. Hum. Genet. 54:145-151(2009).
RN   [23]
RP   VARIANTS MLIIIA GLN-4; TYR-15; VAL-190; GLN-334; PHE-399; SER-468;
RP   TYR-505; ARG-956 AND GLY-1018, AND VARIANT MLII LEU-348.
RX   PubMed=19617216; DOI=10.1136/jmg.2009.067736;
RA   Cathey S.S., Leroy J.G., Wood T., Eaves K., Simensen R.J., Kudo M.,
RA   Stevenson R.E., Friez M.J.;
RT   "Phenotype and genotype in mucolipidoses II and III alpha/beta: a
RT   study of 61 probands.";
RL   J. Med. Genet. 47:38-48(2010).
RN   [24]
RP   VARIANTS SER-455; LEU-625 AND LYS-1200, AND POSSIBLE INVOLVEMENT IN
RP   PERSISTENT STUTTERING.
RX   PubMed=20147709; DOI=10.1056/NEJMoa0902630;
RA   Kang C., Riazuddin S., Mundorff J., Krasnewich D., Friedman P.,
RA   Mullikin J.C., Drayna D.;
RT   "Mutations in the lysosomal enzyme-targeting pathway and persistent
RT   stuttering.";
RL   N. Engl. J. Med. 362:677-685(2010).
RN   [25]
RP   VARIANT MLII CYS-986.
RX   PubMed=22495880; DOI=10.1002/ajmg.a.35295;
RA   Coutinho M.F., Santos L.S., Girisha K.M., Satyamoorthy K., Lacerda L.,
RA   Prata M.J., Alves S.;
RT   "Mucolipidosis type II alpha/beta with a homozygous missense mutation
RT   in the GNPTAB gene.";
RL   Am. J. Med. Genet. A 158A:1225-1228(2012).
RN   [26]
RP   VARIANT MLIIIA GLN-4, AND CHARACTERIZATION OF VARIANT MLIIIA GLN-4.
RX   PubMed=24045841; DOI=10.1038/ejhg.2013.207;
RA   Leroy J.G., Sillence D., Wood T., Barnes J., Lebel R.R., Friez M.J.,
RA   Stevenson R.E., Steet R., Cathey S.S.;
RT   "A novel intermediate mucolipidosis II/IIIalphabeta caused by GNPTAB
RT   mutation in the cytosolic N-terminal domain.";
RL   Eur. J. Hum. Genet. 22:594-601(2014).
RN   [27]
RP   VARIANT MLII LEU-81, AND VARIANTS MLIIIA PHE-399; THR-403 AND TYR-505.
RX   PubMed=23566849; DOI=10.1016/j.gene.2013.03.105;
RA   Cury G.K., Matte U., Artigalas O., Alegra T., Velho R.V., Sperb F.,
RA   Burin M.G., Ribeiro E.M., Lourenco C.M., Kim C.A., Valadares E.R.,
RA   Galera M.F., Acosta A.X., Schwartz I.V.;
RT   "Mucolipidosis II and III alpha/beta in Brazil: analysis of the GNPTAB
RT   gene.";
RL   Gene 524:59-64(2013).
RN   [28]
RP   VARIANTS MLII LEU-81; CYS-986 AND MET-1236, VARIANT MLIIIA PHE-399,
RP   CHARACTERIZATION OF VARIANTS MLII LEU-81; CYS-986 AND MET-1236,
RP   CHARACTERIZATION OF VARIANT MLIIIA PHE-399, SUBCELLULAR LOCATION,
RP   PROTEOLYTIC PROCESSING, AND GLYCOSYLATION.
RX   PubMed=24375680; DOI=10.1002/humu.22502;
RA   De Pace R., Coutinho M.F., Koch-Nolte F., Haag F., Prata M.J.,
RA   Alves S., Braulke T., Pohl S.;
RT   "Mucolipidosis II-related mutations inhibit the exit from the
RT   endoplasmic reticulum and proteolytic cleavage of GlcNAc-1-
RT   phosphotransferase precursor protein (GNPTAB).";
RL   Hum. Mutat. 35:368-376(2014).
RN   [29]
RP   VARIANT MLII ASN-732, CHARACTERIZATION OF VARIANT MLII ASN-732,
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=23733939; DOI=10.1073/pnas.1308453110;
RA   Qian Y., Flanagan-Steet H., van Meel E., Steet R., Kornfeld S.A.;
RT   "The DMAP interaction domain of UDP-GlcNAc:lysosomal enzyme N-
RT   acetylglucosamine-1-phosphotransferase is a substrate recognition
RT   module.";
RL   Proc. Natl. Acad. Sci. U.S.A. 110:10246-10251(2013).
RN   [30]
RP   VARIANTS THR-592 AND TRP-785.
RX   PubMed=24767253; DOI=10.1186/1750-1172-9-59;
RA   Fernandez-Marmiesse A., Morey M., Pineda M., Eiris J., Couce M.L.,
RA   Castro-Gago M., Fraga J.M., Lacerda L., Gouveia S., Perez-Poyato M.S.,
RA   Armstrong J., Castineiras D., Cocho J.A.;
RT   "Assessment of a targeted resequencing assay as a support tool in the
RT   diagnosis of lysosomal storage disorders.";
RL   Orphanet J. Rare Dis. 9:59-59(2014).
RN   [31]
RP   VARIANTS MLIIIA MET-644 AND THR-1223 DEL, CHARACTERIZATION OF VARIANTS
RP   MLIIIA PHE-399; THR-403; TYR-505; ARG-575; MET-644 AND THR-1223 DEL,
RP   CHARACTERIZATION OF VARIANT MLII 937-TYR--MET-972 DEL, MUTAGENESIS OF
RP   ILE-346 AND TRP-357, SUBCELLULAR LOCATION, AND PROTEOLYTIC CLEAVAGE.
RX   PubMed=25788519; DOI=10.1093/hmg/ddv100;
RA   Velho R.V., De Pace R., Kluender S., Sperb-Ludwig F., Lourenco C.M.,
RA   Schwartz I.V., Braulke T., Pohl S.;
RT   "Analyses of disease-related GNPTAB mutations define a novel GlcNAc-1-
RT   phosphotransferase interaction domain and an alternative site-1
RT   protease cleavage site.";
RL   Hum. Mol. Genet. 24:3497-3505(2015).
RN   [32]
RP   VARIANT MLII CYS-986, AND VARIANT ARG-523.
RX   PubMed=24798265; DOI=10.1007/8904_2014_308;
RA   Cobos P.N., Steglich C., Santer R., Lukacs Z., Gal A.;
RT   "Dried blood spots allow targeted screening to diagnose
RT   mucopolysaccharidosis and mucolipidosis.";
RL   JIMD Rep. 15:123-132(2015).
RN   [33]
RP   VARIANT LYS-1200.
RX   PubMed=27535533; DOI=10.1038/nature19057;
RG   Exome Aggregation Consortium;
RA   Lek M., Karczewski K.J., Minikel E.V., Samocha K.E., Banks E.,
RA   Fennell T., O'Donnell-Luria A.H., Ware J.S., Hill A.J., Cummings B.B.,
RA   Tukiainen T., Birnbaum D.P., Kosmicki J.A., Duncan L.E., Estrada K.,
RA   Zhao F., Zou J., Pierce-Hoffman E., Berghout J., Cooper D.N.,
RA   Deflaux N., DePristo M., Do R., Flannick J., Fromer M., Gauthier L.,
RA   Goldstein J., Gupta N., Howrigan D., Kiezun A., Kurki M.I.,
RA   Moonshine A.L., Natarajan P., Orozco L., Peloso G.M., Poplin R.,
RA   Rivas M.A., Ruano-Rubio V., Rose S.A., Ruderfer D.M., Shakir K.,
RA   Stenson P.D., Stevens C., Thomas B.P., Tiao G., Tusie-Luna M.T.,
RA   Weisburd B., Won H.H., Yu D., Altshuler D.M., Ardissino D.,
RA   Boehnke M., Danesh J., Donnelly S., Elosua R., Florez J.C.,
RA   Gabriel S.B., Getz G., Glatt S.J., Hultman C.M., Kathiresan S.,
RA   Laakso M., McCarroll S., McCarthy M.I., McGovern D., McPherson R.,
RA   Neale B.M., Palotie A., Purcell S.M., Saleheen D., Scharf J.M.,
RA   Sklar P., Sullivan P.F., Tuomilehto J., Tsuang M.T., Watkins H.C.,
RA   Wilson J.G., Daly M.J., MacArthur D.G.;
RT   "Analysis of protein-coding genetic variation in 60,706 humans.";
RL   Nature 536:285-291(2016).
CC   -!- FUNCTION: Catalyzes the formation of mannose 6-phosphate (M6P)
CC       markers on high mannose type oligosaccharides in the Golgi
CC       apparatus. M6P residues are required to bind to the M6P receptors
CC       (MPR), which mediate the vesicular transport of lysosomal enzymes
CC       to the endosomal/prelysosomal compartment.
CC       {ECO:0000269|PubMed:19955174, ECO:0000269|PubMed:23733939}.
CC   -!- CATALYTIC ACTIVITY: UDP-N-acetyl-D-glucosamine + lysosomal-enzyme
CC       D-mannose = UMP + lysosomal-enzyme N-acetyl-D-glucosaminyl-
CC       phospho-D-mannose. {ECO:0000269|PubMed:19955174}.
CC   -!- SUBUNIT: Hexamer of two alpha, two beta and two gamma (GNPTG)
CC       subunits; disulfide-linked. The alpha and/or the beta subunits of
CC       the enzyme constitute the catalytic subunits.
CC       {ECO:0000269|PubMed:19955174}.
CC   -!- INTERACTION:
CC       Q8WTP8:AEN; NbExp=3; IntAct=EBI-1104907, EBI-8637627;
CC       Q86YD7:FAM90A1; NbExp=3; IntAct=EBI-1104907, EBI-6658203;
CC       P25786:PSMA1; NbExp=3; IntAct=EBI-1104907, EBI-359352;
CC       Q96FJ0:STAMBPL1; NbExp=3; IntAct=EBI-1104907, EBI-745021;
CC       P15622-3:ZNF250; NbExp=3; IntAct=EBI-1104907, EBI-10177272;
CC   -!- SUBCELLULAR LOCATION: N-acetylglucosamine-1-phosphotransferase
CC       subunit alpha: Golgi apparatus membrane
CC       {ECO:0000269|PubMed:16120602, ECO:0000269|PubMed:16200072,
CC       ECO:0000269|PubMed:21719679, ECO:0000269|PubMed:23733939,
CC       ECO:0000269|PubMed:24375680, ECO:0000269|PubMed:25788519}; Single-
CC       pass type I membrane protein {ECO:0000305}.
CC   -!- SUBCELLULAR LOCATION: N-acetylglucosamine-1-phosphotransferase
CC       subunit beta: Golgi apparatus membrane
CC       {ECO:0000269|PubMed:16120602, ECO:0000269|PubMed:16200072,
CC       ECO:0000269|PubMed:21719679, ECO:0000269|PubMed:23733939,
CC       ECO:0000269|PubMed:24375680}; Single-pass type II membrane protein
CC       {ECO:0000305}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q3T906-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q3T906-2; Sequence=VSP_017338, VSP_017339;
CC   -!- TISSUE SPECIFICITY: Expressed in the heart, whole brain, placenta,
CC       lung, liver, skeletal muscle, kidney and pancreas.
CC       {ECO:0000269|PubMed:16120602}.
CC   -!- DOMAIN: The DMAP-interaction domain mediates substrate
CC       recognition. It specifically recognizes a conformation-dependent
CC       protein determinant present in acid hydrolases (PubMed:23733939).
CC       {ECO:0000269|PubMed:23733939}.
CC   -!- PTM: The alpha- and beta-subunits are generated by a proteolytic
CC       cleavage by MBTPS1 protease at the Lys-928-Asp-929 bond.
CC       {ECO:0000269|PubMed:21719679, ECO:0000269|PubMed:24375680,
CC       ECO:0000269|PubMed:25788519}.
CC   -!- DISEASE: Mucolipidosis type II (MLII) [MIM:252500]: Fatal,
CC       autosomal recessive, lysosomal storage disorder characterized by
CC       severe clinical and radiologic features, peculiar fibroblast
CC       inclusions, and no excessive mucopolysacchariduria. Congenital
CC       dislocation of the hip, thoracic deformities, hernia, and
CC       hyperplastic gums are evident soon after birth.
CC       {ECO:0000269|PubMed:16200072, ECO:0000269|PubMed:16835905,
CC       ECO:0000269|PubMed:19197337, ECO:0000269|PubMed:19617216,
CC       ECO:0000269|PubMed:19634183, ECO:0000269|PubMed:19938078,
CC       ECO:0000269|PubMed:22495880, ECO:0000269|PubMed:23566849,
CC       ECO:0000269|PubMed:23733939, ECO:0000269|PubMed:23773965,
CC       ECO:0000269|PubMed:24375680, ECO:0000269|PubMed:24798265,
CC       ECO:0000269|PubMed:25505245, ECO:0000269|PubMed:25788519}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- DISEASE: Mucolipidosis type III complementation group A (MLIIIA)
CC       [MIM:252600]: Autosomal recessive disease of lysosomal enzyme
CC       targeting. Clinically MLIII is characterized by restricted joint
CC       mobility, skeletal dysplasia, and short stature. Mildly coarsened
CC       facial features and thickening of the skin have been described.
CC       Cardiac valvular disease and corneal clouding may also occur. Half
CC       of the reported patients show learning disabilities or mental
CC       retardation. {ECO:0000269|PubMed:16094673,
CC       ECO:0000269|PubMed:16465621, ECO:0000269|PubMed:16630736,
CC       ECO:0000269|PubMed:17034777, ECO:0000269|PubMed:19197337,
CC       ECO:0000269|PubMed:19617216, ECO:0000269|PubMed:19634183,
CC       ECO:0000269|PubMed:19938078, ECO:0000269|PubMed:23566849,
CC       ECO:0000269|PubMed:24045841, ECO:0000269|PubMed:24375680,
CC       ECO:0000269|PubMed:24550498, ECO:0000269|PubMed:25505245,
CC       ECO:0000269|PubMed:25788519}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Note=Genetic variations in GNPTAB have been suggested to
CC       play a role in susceptibility to persistent stuttering. Stuttering
CC       is a common speech disorder characterized by repetitions,
CC       prolongations, and interruptions in the flow of speech.
CC       {ECO:0000269|PubMed:20147709}.
CC   -!- MISCELLANEOUS: Due to the low pH in the endosomal/prelysosomal
CC       compartment, the lysosomal enzyme-MPR complex dissociates and then
CC       the enzyme is delivered to the lysosome. Between 5% and 20% of
CC       newly synthesized lysosomal enzymes escape the binding to the MPR
CC       in the Golgi apparatus and are secreted.
CC   -!- MISCELLANEOUS: Stealth proteins are part of a protein family that
CC       is conserved from bacteria to higher eukaryotes. Family members
CC       were first identified in microbes as proteins that help pathogens
CC       to elude the host innate immune system. Microbial stealth proteins
CC       are most likely involved in the biosynthesis of
CC       exopolysaccharides. Stealth proteins are predicted to function as
CC       hexose-1-phosphoryltransferases.
CC   -!- SIMILARITY: Belongs to the stealth family. {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AM085438; CAJ30014.1; -; mRNA.
DR   EMBL; AY687932; AAV98624.1; -; mRNA.
DR   EMBL; BC071687; AAH71687.1; -; mRNA.
DR   EMBL; BC042615; AAH42615.1; -; mRNA.
DR   EMBL; BC131787; AAI31788.1; -; mRNA.
DR   EMBL; AK056137; BAB71102.1; -; mRNA.
DR   EMBL; AB033034; BAA86522.2; -; mRNA.
DR   CCDS; CCDS9088.1; -. [Q3T906-1]
DR   RefSeq; NP_077288.2; NM_024312.4. [Q3T906-1]
DR   UniGene; Hs.46850; -.
DR   PDB; 2N6D; NMR; -; A=135-305.
DR   PDBsum; 2N6D; -.
DR   ProteinModelPortal; Q3T906; -.
DR   SMR; Q3T906; -.
DR   BioGrid; 122576; 25.
DR   IntAct; Q3T906; 14.
DR   STRING; 9606.ENSP00000299314; -.
DR   iPTMnet; Q3T906; -.
DR   PhosphoSitePlus; Q3T906; -.
DR   BioMuta; GNPTAB; -.
DR   DMDM; 90185244; -.
DR   EPD; Q3T906; -.
DR   MaxQB; Q3T906; -.
DR   PaxDb; Q3T906; -.
DR   PeptideAtlas; Q3T906; -.
DR   PRIDE; Q3T906; -.
DR   Ensembl; ENST00000299314; ENSP00000299314; ENSG00000111670. [Q3T906-1]
DR   Ensembl; ENST00000549940; ENSP00000449150; ENSG00000111670. [Q3T906-2]
DR   GeneID; 79158; -.
DR   KEGG; hsa:79158; -.
DR   UCSC; uc001tit.4; human. [Q3T906-1]
DR   CTD; 79158; -.
DR   DisGeNET; 79158; -.
DR   GeneCards; GNPTAB; -.
DR   GeneReviews; GNPTAB; -.
DR   HGNC; HGNC:29670; GNPTAB.
DR   HPA; HPA017754; -.
DR   HPA; HPA042343; -.
DR   MalaCards; GNPTAB; -.
DR   MIM; 252500; phenotype.
DR   MIM; 252600; phenotype.
DR   MIM; 607840; gene.
DR   neXtProt; NX_Q3T906; -.
DR   OpenTargets; ENSG00000111670; -.
DR   Orphanet; 576; Mucolipidosis type 2.
DR   Orphanet; 577; Mucolipidosis type 3.
DR   PharmGKB; PA128394710; -.
DR   eggNOG; ENOG410IEF9; Eukaryota.
DR   eggNOG; ENOG410XYNB; LUCA.
DR   GeneTree; ENSGT00390000006747; -.
DR   HOVERGEN; HBG057712; -.
DR   InParanoid; Q3T906; -.
DR   KO; K08239; -.
DR   OMA; MFPEEFD; -.
DR   OrthoDB; EOG091G0C78; -.
DR   PhylomeDB; Q3T906; -.
DR   TreeFam; TF324175; -.
DR   BRENDA; 2.7.8.17; 2681.
DR   ChiTaRS; GNPTAB; human.
DR   GenomeRNAi; 79158; -.
DR   PRO; PR:Q3T906; -.
DR   Proteomes; UP000005640; Chromosome 12.
DR   Bgee; ENSG00000111670; -.
DR   CleanEx; HS_GNPTAB; -.
DR   ExpressionAtlas; Q3T906; baseline and differential.
DR   Genevisible; Q3T906; HS.
DR   GO; GO:0005794; C:Golgi apparatus; IDA:UniProtKB.
DR   GO; GO:0000139; C:Golgi membrane; IDA:UniProtKB.
DR   GO; GO:0016021; C:integral component of membrane; IEA:UniProtKB-KW.
DR   GO; GO:0005509; F:calcium ion binding; IEA:InterPro.
DR   GO; GO:0003976; F:UDP-N-acetylglucosamine-lysosomal-enzyme N-acetylglucosaminephosphotransferase activity; IDA:UniProtKB.
DR   GO; GO:0046835; P:carbohydrate phosphorylation; IDA:UniProtKB.
DR   GO; GO:0007040; P:lysosome organization; IMP:UniProtKB.
DR   GO; GO:0016256; P:N-glycan processing to lysosome; IMP:UniProtKB.
DR   GO; GO:0033299; P:secretion of lysosomal enzymes; IEA:Ensembl.
DR   InterPro; IPR010506; DMAP1-bd.
DR   InterPro; IPR018247; EF_Hand_1_Ca_BS.
DR   InterPro; IPR002048; EF_hand_dom.
DR   InterPro; IPR000800; Notch_dom.
DR   InterPro; IPR031358; Stealth_CR1.
DR   InterPro; IPR021520; Stealth_CR2.
DR   InterPro; IPR031357; Stealth_CR3.
DR   InterPro; IPR031356; Stealth_CR4.
DR   Pfam; PF06464; DMAP_binding; 1.
DR   Pfam; PF00066; Notch; 2.
DR   Pfam; PF17101; Stealth_CR1; 1.
DR   Pfam; PF11380; Stealth_CR2; 1.
DR   Pfam; PF17102; Stealth_CR3; 1.
DR   Pfam; PF17103; Stealth_CR4; 1.
DR   SMART; SM01137; DMAP_binding; 1.
DR   SMART; SM00004; NL; 2.
DR   SUPFAM; SSF90193; SSF90193; 1.
DR   PROSITE; PS00018; EF_HAND_1; 1.
DR   PROSITE; PS50222; EF_HAND_2; 1.
DR   PROSITE; PS50258; LNR; 2.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Calcium; Complete proteome;
KW   Disease mutation; Disulfide bond; Glycoprotein; Golgi apparatus;
KW   Membrane; Metal-binding; Mucolipidosis; Polymorphism;
KW   Reference proteome; Repeat; Signal-anchor; Transferase; Transmembrane;
KW   Transmembrane helix.
FT   CHAIN         1    928       N-acetylglucosamine-1-phosphotransferase
FT                                subunit alpha.
FT                                /FTId=PRO_0000225008.
FT   CHAIN       929   1256       N-acetylglucosamine-1-phosphotransferase
FT                                subunit beta.
FT                                /FTId=PRO_0000225009.
FT   TRANSMEM     22     42       Helical. {ECO:0000255}.
FT   TRANSMEM   1215   1235       Helical. {ECO:0000255}.
FT   REPEAT      438    473       LNR 1.
FT   REPEAT      505    545       LNR 2.
FT   DOMAIN      700    813       DMAP-interaction.
FT   DOMAIN     1005   1040       EF-hand. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00448}.
FT   CA_BIND    1018   1029       {ECO:0000255|PROSITE-ProRule:PRU00448}.
FT   COMPBIAS    465    498       Gly-rich.
FT   METAL       449    449       Calcium. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00525}.
FT   METAL       464    464       Calcium. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00525}.
FT   METAL       467    467       Calcium. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00525}.
FT   METAL       516    516       Calcium. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00525}.
FT   METAL       531    531       Calcium. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00525}.
FT   METAL       534    534       Calcium. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00525}.
FT   SITE        928    929       Cleavage; by MBTPS1.
FT   CARBOHYD     83     83       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    114    114       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    148    148       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    179    179       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    250    250       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    614    614       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    699    699       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:19159218}.
FT   CARBOHYD    729    729       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    829    829       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD   1009   1009       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD   1129   1129       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   DISULFID    438    461       {ECO:0000255|PROSITE-ProRule:PRU00525}.
FT   DISULFID    452    468       {ECO:0000255|PROSITE-ProRule:PRU00525}.
FT   DISULFID    505    528       {ECO:0000255|PROSITE-ProRule:PRU00525}.
FT   DISULFID    519    535       {ECO:0000255|PROSITE-ProRule:PRU00525}.
FT   VAR_SEQ     471    490       NSGGSRYIAGGGGTGSIGVG -> KDVLNCNSFIFMEYFLL
FT                                NHY (in isoform 2).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_017338.
FT   VAR_SEQ     491   1256       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_017339.
FT   VARIANT       4      4       K -> Q (in MLIIIA; also found in patients
FT                                with intermediate phenotype between MLII
FT                                and MLIIIA; no effect on protein
FT                                abundance; decreased retention in the
FT                                Golgi; mistargeted to lysosomes and
FT                                plasma membrane; decreased UDP-N-
FT                                acetylglucosamine-lysosomal-enzyme N-
FT                                acetylglucosaminephosphotransferase
FT                                activity; dbSNP:rs34159654).
FT                                {ECO:0000269|PubMed:16465621,
FT                                ECO:0000269|PubMed:19617216,
FT                                ECO:0000269|PubMed:19938078,
FT                                ECO:0000269|PubMed:24045841,
FT                                ECO:0000269|PubMed:24550498,
FT                                ECO:0000269|PubMed:25505245}.
FT                                /FTId=VAR_027509.
FT   VARIANT      15     15       S -> Y (in MLIIIA; unknown pathological
FT                                significance; no effect on protein
FT                                abundance; decreased protein cleavage
FT                                into alpha and beta subunits; decreased
FT                                retention in the Golgi; mistargeted to
FT                                lysosomes and plasma membrane; decreased
FT                                UDP-N-acetylglucosamine-lysosomal-enzyme
FT                                N-acetylglucosaminephosphotransferase
FT                                activity; dbSNP:rs281864947).
FT                                {ECO:0000269|PubMed:19617216,
FT                                ECO:0000269|PubMed:24550498,
FT                                ECO:0000269|PubMed:25505245}.
FT                                /FTId=VAR_073124.
FT   VARIANT      81     81       W -> L (in MLII; no effect on protein
FT                                abundance; decreased localization to the
FT                                Golgi; defects in protein cleavage into
FT                                alpha and beta subunits; loss of UDP-N-
FT                                acetylglucosamine-lysosomal-enzyme N-
FT                                acetylglucosaminephosphotransferase
FT                                activity; dbSNP:rs281864953).
FT                                {ECO:0000269|PubMed:23566849,
FT                                ECO:0000269|PubMed:24375680,
FT                                ECO:0000269|PubMed:25505245}.
FT                                /FTId=VAR_070831.
FT   VARIANT     182    182       V -> D (in MLII; unknown pathological
FT                                significance; decreased localization to
FT                                the Golgi; decreased UDP-N-
FT                                acetylglucosamine-lysosomal-enzyme N-
FT                                acetylglucosaminephosphotransferase
FT                                activity; dbSNP:rs281864958).
FT                                {ECO:0000269|PubMed:19938078,
FT                                ECO:0000269|PubMed:25505245}.
FT                                /FTId=VAR_073125.
FT   VARIANT     190    190       D -> V (in MLIIIA; also found in patients
FT                                with intermediate phenotype between MLII
FT                                and MLIIIA; unknown pathological
FT                                significance; no effect on protein
FT                                abundance; no effect on localization to
FT                                the Golgi; no effect on protein cleavage
FT                                into alpha and beta subunits; decreased
FT                                UDP-N-acetylglucosamine-lysosomal-enzyme
FT                                N-acetylglucosaminephosphotransferase
FT                                activity; dbSNP:rs34946266).
FT                                {ECO:0000269|PubMed:19617216}.
FT                                /FTId=VAR_053545.
FT   VARIANT     205    205       Q -> P (in MLII; unknown pathological
FT                                significance; dbSNP:rs281864959).
FT                                {ECO:0000269|PubMed:19938078}.
FT                                /FTId=VAR_073126.
FT   VARIANT     334    334       R -> L (in MLII; no effect on protein
FT                                abundance; loss of localization to the
FT                                Golgi; loss of protein cleavage into
FT                                alpha and beta subunits; loss of UDP-N-
FT                                acetylglucosamine-lysosomal-enzyme N-
FT                                acetylglucosaminephosphotransferase
FT                                activity; dbSNP:rs281864970).
FT                                {ECO:0000269|PubMed:19197337,
FT                                ECO:0000269|PubMed:25505245}.
FT                                /FTId=VAR_073127.
FT   VARIANT     334    334       R -> Q (in MLIIIA; no effect on protein
FT                                abundance; loss of localization to the
FT                                Golgi; loss of protein cleavage into
FT                                alpha and beta subunits; loss of UDP-N-
FT                                acetylglucosamine-lysosomal-enzyme N-
FT                                acetylglucosaminephosphotransferase
FT                                activity; dbSNP:rs281864970).
FT                                {ECO:0000269|PubMed:19617216,
FT                                ECO:0000269|PubMed:25505245}.
FT                                /FTId=VAR_073128.
FT   VARIANT     348    348       I -> L (in MLII; unknown pathological
FT                                significance; no effect on protein
FT                                abundance; no effect on localization to
FT                                the Golgi; no effect on protein cleavage
FT                                into alpha and beta subunits; decreased
FT                                UDP-N-acetylglucosamine-lysosomal-enzyme
FT                                N-acetylglucosaminephosphotransferase
FT                                activity; dbSNP:rs7958709).
FT                                {ECO:0000269|PubMed:19617216,
FT                                ECO:0000269|PubMed:25505245}.
FT                                /FTId=VAR_027510.
FT   VARIANT     374    374       F -> L (in MLII and MLIIIA; no effect on
FT                                protein abundance; no effect on
FT                                localization to the Golgi; loss of UDP-N-
FT                                acetylglucosamine-lysosomal-enzyme N-
FT                                acetylglucosaminephosphotransferase
FT                                activity; dbSNP:rs137852900).
FT                                {ECO:0000269|PubMed:19197337,
FT                                ECO:0000269|PubMed:25505245}.
FT                                /FTId=VAR_062807.
FT   VARIANT     399    399       S -> F (in MLIIIA; no effect on protein
FT                                abundance; loss of localization to the
FT                                Golgi; defects in protein cleavage into
FT                                alpha and beta subunits; decreased UDP-N-
FT                                acetylglucosamine-lysosomal-enzyme N-
FT                                acetylglucosaminephosphotransferase
FT                                activity; dbSNP:rs281865026).
FT                                {ECO:0000269|PubMed:16630736,
FT                                ECO:0000269|PubMed:19617216,
FT                                ECO:0000269|PubMed:23566849,
FT                                ECO:0000269|PubMed:24375680,
FT                                ECO:0000269|PubMed:25505245,
FT                                ECO:0000269|PubMed:25788519}.
FT                                /FTId=VAR_062808.
FT   VARIANT     403    403       I -> T (in MLIIIA; loss of localization
FT                                to the Golgi; loss of protein cleavage
FT                                into alpha and beta subunits; decreased
FT                                UDP-N-acetylglucosamine-lysosomal-enzyme
FT                                N-acetylglucosaminephosphotransferase
FT                                activity; dbSNP:rs281864973).
FT                                {ECO:0000269|PubMed:19634183,
FT                                ECO:0000269|PubMed:23566849,
FT                                ECO:0000269|PubMed:25505245,
FT                                ECO:0000269|PubMed:25788519}.
FT                                /FTId=VAR_062809.
FT   VARIANT     407    407       D -> A (in MLIIIA; no effect on protein
FT                                abundance; no effect on localization to
FT                                the Golgi; no effect on protein cleavage
FT                                into alpha and beta subunits; decreased
FT                                UDP-N-acetylglucosamine-lysosomal-enzyme
FT                                N-acetylglucosaminephosphotransferase
FT                                activity; dbSNP:rs137852895).
FT                                {ECO:0000269|PubMed:16094673,
FT                                ECO:0000269|PubMed:25505245}.
FT                                /FTId=VAR_025416.
FT   VARIANT     442    442       C -> Y (in MLIIIA; no effect on
FT                                localization to the Golgi; no effect on
FT                                protein cleavage into alpha and beta
FT                                subunits; loss of UDP-N-
FT                                acetylglucosamine-lysosomal-enzyme N-
FT                                acetylglucosaminephosphotransferase
FT                                activity toward some substrates;
FT                                dbSNP:rs281864975).
FT                                {ECO:0000269|PubMed:19634183,
FT                                ECO:0000269|PubMed:25505245}.
FT                                /FTId=VAR_062810.
FT   VARIANT     455    455       A -> S (rare variant; found in
FT                                individuals suffering from stuttering;
FT                                unknown pathological significance;
FT                                dbSNP:rs137853822).
FT                                {ECO:0000269|PubMed:20147709}.
FT                                /FTId=VAR_073219.
FT   VARIANT     461    461       C -> G (in MLIIIA; no effect on protein
FT                                abundance; no effect on localization to
FT                                the Golgi; no effect on protein cleavage
FT                                into alpha and beta subunits; loss of
FT                                UDP-N-acetylglucosamine-lysosomal-enzyme
FT                                N-acetylglucosaminephosphotransferase
FT                                activity toward some substrates;
FT                                dbSNP:rs281864977).
FT                                {ECO:0000269|PubMed:19634183,
FT                                ECO:0000269|PubMed:25505245}.
FT                                /FTId=VAR_062811.
FT   VARIANT     468    468       C -> S (in MLIIIA; patients with
FT                                intermediate phenotype between MLII and
FT                                MLIIIA; no effect on protein abundance;
FT                                no effect on localization to the Golgi;
FT                                no effect on protein cleavage into alpha
FT                                and beta subunits; loss of UDP-N-
FT                                acetylglucosamine-lysosomal-enzyme N-
FT                                acetylglucosaminephosphotransferase
FT                                activity toward some substrates;
FT                                dbSNP:rs281864979).
FT                                {ECO:0000269|PubMed:19617216,
FT                                ECO:0000269|PubMed:25505245}.
FT                                /FTId=VAR_073129.
FT   VARIANT     505    505       C -> Y (in MLIIIA; unknown pathological
FT                                significance; decreased localization to
FT                                the Golgi; decreased protein cleavage
FT                                into alpha and beta subunits; decreased
FT                                UDP-N-acetylglucosamine-lysosomal-enzyme
FT                                N-acetylglucosaminephosphotransferase
FT                                activity; reduces protein abundance;
FT                                dbSNP:rs281864980).
FT                                {ECO:0000269|PubMed:19617216,
FT                                ECO:0000269|PubMed:23566849,
FT                                ECO:0000269|PubMed:25505245,
FT                                ECO:0000269|PubMed:25788519}.
FT                                /FTId=VAR_070832.
FT   VARIANT     523    523       C -> R (found in a patient with
FT                                mucolipidosis type II or III; unknown
FT                                pathological significance; decreased
FT                                localization to the Golgi; decreased
FT                                protein cleavage into alpha and beta
FT                                subunits; decreased UDP-N-
FT                                acetylglucosamine-lysosomal-enzyme N-
FT                                acetylglucosaminephosphotransferase
FT                                activity). {ECO:0000269|PubMed:24798265,
FT                                ECO:0000269|PubMed:25505245}.
FT                                /FTId=VAR_073130.
FT   VARIANT     575    575       G -> R (in MLIIIA; significantly reduces
FT                                protein cleavage into alpha and beta
FT                                subunits; reduces protein abundance;
FT                                significantly decreased localization to
FT                                the Golgi; significantly reduces UDP-N-
FT                                acetylglucosamine-lysosomal-enzyme N-
FT                                acetylglucosaminephosphotransferase).
FT                                {ECO:0000269|PubMed:25788519}.
FT                                /FTId=VAR_074206.
FT   VARIANT     587    587       R -> P (in MLIIIA; decreased localization
FT                                to the Golgi; decreased UDP-N-
FT                                acetylglucosamine-lysosomal-enzyme N-
FT                                acetylglucosaminephosphotransferase
FT                                activity). {ECO:0000269|PubMed:17034777,
FT                                ECO:0000269|PubMed:25505245}.
FT                                /FTId=VAR_073131.
FT   VARIANT     592    592       A -> T (found in a patient with
FT                                mucolipidosis type II or III; unknown
FT                                pathological significance; decreased
FT                                localization to the Golgi; decreased UDP-
FT                                N-acetylglucosamine-lysosomal-enzyme N-
FT                                acetylglucosaminephosphotransferase
FT                                activity; dbSNP:rs149390820).
FT                                {ECO:0000269|PubMed:24767253,
FT                                ECO:0000269|PubMed:25505245}.
FT                                /FTId=VAR_073132.
FT   VARIANT     625    625       F -> L (rare variant; found in
FT                                individuals suffering from stuttering;
FT                                unknown pathological significance;
FT                                dbSNP:rs137853823).
FT                                {ECO:0000269|PubMed:20147709}.
FT                                /FTId=VAR_073220.
FT   VARIANT     644    644       T -> M (in MLIIIA; reduces protein
FT                                cleavage into alpha and beta subunits;
FT                                reduces protein abundance; no effect on
FT                                subcellular location in Golgi apparatus;
FT                                mildly affects UDP-N-acetylglucosamine-
FT                                lysosomal-enzyme N-
FT                                acetylglucosaminephosphotransferase;
FT                                dbSNP:rs386765812).
FT                                {ECO:0000269|PubMed:25788519}.
FT                                /FTId=VAR_074207.
FT   VARIANT     662    662       A -> G (in dbSNP:rs142172397).
FT                                {ECO:0000269|PubMed:16094673}.
FT                                /FTId=VAR_025417.
FT   VARIANT     732    732       K -> N (in MLII; no effect on
FT                                localization to the Golgi; loss of UDP-N-
FT                                acetylglucosamine-lysosomal-enzyme N-
FT                                acetylglucosaminephosphotransferase
FT                                activity toward some substrates;
FT                                dbSNP:rs281864989).
FT                                {ECO:0000269|PubMed:19938078,
FT                                ECO:0000269|PubMed:23733939,
FT                                ECO:0000269|PubMed:25505245}.
FT                                /FTId=VAR_070833.
FT   VARIANT     785    785       L -> W (found in a patient with
FT                                mucolipidosis type II or III; unknown
FT                                pathological significance; no effect on
FT                                localization to the Golgi; loss of UDP-N-
FT                                acetylglucosamine-lysosomal-enzyme N-
FT                                acetylglucosaminephosphotransferase
FT                                activity toward some substrates;
FT                                dbSNP:rs144060383).
FT                                {ECO:0000269|PubMed:24767253,
FT                                ECO:0000269|PubMed:25505245}.
FT                                /FTId=VAR_073133.
FT   VARIANT     926    926       Q -> P (in MLIIIA; no effect on
FT                                localization to the Golgi; loss of
FT                                protein cleavage into alpha and beta
FT                                subunits; loss of UDP-N-
FT                                acetylglucosamine-lysosomal-enzyme N-
FT                                acetylglucosaminephosphotransferase
FT                                activity; dbSNP:rs281865002).
FT                                {ECO:0000269|PubMed:19634183,
FT                                ECO:0000269|PubMed:25505245}.
FT                                /FTId=VAR_062812.
FT   VARIANT     928    928       K -> R (in MLII; unknown pathological
FT                                significance; dbSNP:rs281865003).
FT                                {ECO:0000269|PubMed:19938078}.
FT                                /FTId=VAR_073134.
FT   VARIANT     937    972       Missing (in MLII; abnormal protein
FT                                cleavage into alpha and beta subunits; no
FT                                effect on protein abundance;
FT                                significantly decreased localization to
FT                                the Golgi; loss of UDP-N-
FT                                acetylglucosamine-lysosomal-enzyme N-
FT                                acetylglucosaminephosphotransferase).
FT                                {ECO:0000269|PubMed:25788519}.
FT                                /FTId=VAR_074208.
FT   VARIANT     955    955       A -> V (in MLII; unknown pathological
FT                                significance; no effect on protein
FT                                abundance; no effect on localization to
FT                                the Golgi; decreased UDP-N-
FT                                acetylglucosamine-lysosomal-enzyme N-
FT                                acetylglucosaminephosphotransferase
FT                                activity; dbSNP:rs138390866).
FT                                {ECO:0000269|PubMed:19938078,
FT                                ECO:0000269|PubMed:25505245}.
FT                                /FTId=VAR_073135.
FT   VARIANT     956    956       H -> R (in MLIIIA; unknown pathological
FT                                significance; dbSNP:rs281865005).
FT                                {ECO:0000269|PubMed:19617216}.
FT                                /FTId=VAR_073136.
FT   VARIANT     956    956       H -> Y (in MLIIIA; no effect on protein
FT                                abundance; no effect on localization to
FT                                the Golgi; dbSNP:rs281865004).
FT                                {ECO:0000269|PubMed:19197337,
FT                                ECO:0000269|PubMed:25505245}.
FT                                /FTId=VAR_062813.
FT   VARIANT     986    986       R -> C (in MLII; decreased protein
FT                                abundance; no effect on localization to
FT                                the Golgi; no effect on protein cleavage
FT                                into alpha and beta subunits; loss of
FT                                UDP-N-acetylglucosamine-lysosomal-enzyme
FT                                N-acetylglucosaminephosphotransferase
FT                                activity; dbSNP:rs769587233).
FT                                {ECO:0000269|PubMed:22495880,
FT                                ECO:0000269|PubMed:24375680,
FT                                ECO:0000269|PubMed:24798265,
FT                                ECO:0000269|PubMed:25505245}.
FT                                /FTId=VAR_070834.
FT   VARIANT    1001   1001       L -> P (in MLII; no effect on protein
FT                                abundance; decreased localization to the
FT                                Golgi; decreased UDP-N-acetylglucosamine-
FT                                lysosomal-enzyme N-
FT                                acetylglucosaminephosphotransferase
FT                                activity; dbSNP:rs281865006).
FT                                {ECO:0000269|PubMed:19634183,
FT                                ECO:0000269|PubMed:25505245}.
FT                                /FTId=VAR_062814.
FT   VARIANT    1018   1018       D -> G (in MLIIIA; patients with
FT                                intermediate phenotype between MLII and
FT                                MLIIIA; unknown pathological
FT                                significance; no effect on protein
FT                                abundance; decreased localization to the
FT                                Golgi; loss of UDP-N-acetylglucosamine-
FT                                lysosomal-enzyme N-
FT                                acetylglucosaminephosphotransferase
FT                                activity; dbSNP:rs281865007).
FT                                {ECO:0000269|PubMed:19617216,
FT                                ECO:0000269|PubMed:25505245}.
FT                                /FTId=VAR_073137.
FT   VARIANT    1054   1054       L -> V (in MLII; unknown pathological
FT                                significance; no effect on localization
FT                                to the Golgi; decreased UDP-N-
FT                                acetylglucosamine-lysosomal-enzyme N-
FT                                acetylglucosaminephosphotransferase
FT                                activity; dbSNP:rs281865010).
FT                                {ECO:0000269|PubMed:19938078,
FT                                ECO:0000269|PubMed:25505245}.
FT                                /FTId=VAR_073138.
FT   VARIANT    1153   1153       N -> S (in MLIIIA; no effect on protein
FT                                abundance; no effect on localization to
FT                                the Golgi; loss of UDP-N-
FT                                acetylglucosamine-lysosomal-enzyme N-
FT                                acetylglucosaminephosphotransferase
FT                                activity; dbSNP:rs281865019).
FT                                {ECO:0000269|PubMed:19197337,
FT                                ECO:0000269|PubMed:25505245}.
FT                                /FTId=VAR_062815.
FT   VARIANT    1200   1200       E -> K (polymorphism; may be a risk
FT                                factor for stuttering;
FT                                dbSNP:rs137853825).
FT                                {ECO:0000269|PubMed:20147709,
FT                                ECO:0000269|PubMed:27535533}.
FT                                /FTId=VAR_073221.
FT   VARIANT    1223   1223       Missing (in MLIIIA; no effect on protein
FT                                cleavage into alpha and beta subunits; no
FT                                effect on protein abundance; no effect on
FT                                subcellular location in cis-Golgi
FT                                apparatus; slightly affects UDP-N-
FT                                acetylglucosamine-lysosomal-enzyme N-
FT                                acetylglucosaminephosphotransferase
FT                                activity). {ECO:0000269|PubMed:25788519}.
FT                                /FTId=VAR_074209.
FT   VARIANT    1236   1236       K -> M (in MLII; decreased protein
FT                                abundance; no effect on localization to
FT                                the Golgi; does not suppress protein
FT                                cleavage into alpha and beta subunits;
FT                                decreased UDP-N-acetylglucosamine-
FT                                lysosomal-enzyme N-
FT                                acetylglucosaminephosphotransferase
FT                                activity). {ECO:0000269|PubMed:16835905,
FT                                ECO:0000269|PubMed:24375680,
FT                                ECO:0000269|PubMed:25505245}.
FT                                /FTId=VAR_027511.
FT   MUTAGEN     346    346       I->A: Partially cleaved by MBTPS1.
FT                                {ECO:0000269|PubMed:25788519}.
FT   MUTAGEN     357    357       W->A: Abolishes proteolytic cleavage by
FT                                MBTPS1. {ECO:0000269|PubMed:25788519}.
FT   MUTAGEN     925    925       R->A: Abolishes proteolytic cleavage by
FT                                MBTPS1. {ECO:0000269|PubMed:21719679}.
FT   MUTAGEN     927    927       L->A: Abolishes proteolytic cleavage by
FT                                MBTPS1. {ECO:0000269|PubMed:21719679}.
FT   MUTAGEN     928    928       K->A: Abolishes proteolytic cleavage by
FT                                MBTPS1. {ECO:0000269|PubMed:21719679}.
FT   CONFLICT    392    392       I -> V (in Ref. 2; AAV98624).
FT                                {ECO:0000305}.
FT   CONFLICT    901    901       Q -> L (in Ref. 2; AAV98624).
FT                                {ECO:0000305}.
FT   STRAND      138    141       {ECO:0000244|PDB:2N6D}.
FT   TURN        151    153       {ECO:0000244|PDB:2N6D}.
FT   TURN        155    157       {ECO:0000244|PDB:2N6D}.
FT   HELIX       159    161       {ECO:0000244|PDB:2N6D}.
FT   STRAND      165    172       {ECO:0000244|PDB:2N6D}.
FT   STRAND      175    184       {ECO:0000244|PDB:2N6D}.
FT   HELIX       188    196       {ECO:0000244|PDB:2N6D}.
FT   STRAND      207    210       {ECO:0000244|PDB:2N6D}.
FT   STRAND      225    231       {ECO:0000244|PDB:2N6D}.
FT   HELIX       240    244       {ECO:0000244|PDB:2N6D}.
FT   HELIX       249    251       {ECO:0000244|PDB:2N6D}.
FT   STRAND      252    256       {ECO:0000244|PDB:2N6D}.
FT   STRAND      262    265       {ECO:0000244|PDB:2N6D}.
FT   STRAND      267    272       {ECO:0000244|PDB:2N6D}.
FT   HELIX       274    280       {ECO:0000244|PDB:2N6D}.
SQ   SEQUENCE   1256 AA;  143622 MW;  8B861154C516943E CRC64;
     MLFKLLQRQT YTCLSHRYGL YVCFLGVVVT IVSAFQFGEV VLEWSRDQYH VLFDSYRDNI
     AGKSFQNRLC LPMPIDVVYT WVNGTDLELL KELQQVREQM EEEQKAMREI LGKNTTEPTK
     KSEKQLECLL THCIKVPMLV LDPALPANIT LKDLPSLYPS FHSASDIFNV AKPKNPSTNV
     SVVVFDSTKD VEDAHSGLLK GNSRQTVWRG YLTTDKEVPG LVLMQDLAFL SGFPPTFKET
     NQLKTKLPEN LSSKVKLLQL YSEASVALLK LNNPKDFQEL NKQTKKNMTI DGKELTISPA
     YLLWDLSAIS QSKQDEDISA SRFEDNEELR YSLRSIERHA PWVRNIFIVT NGQIPSWLNL
     DNPRVTIVTH QDVFRNLSHL PTFSSPAIES HIHRIEGLSQ KFIYLNDDVM FGKDVWPDDF
     YSHSKGQKVY LTWPVPNCAE GCPGSWIKDG YCDKACNNSA CDWDGGDCSG NSGGSRYIAG
     GGGTGSIGVG QPWQFGGGIN SVSYCNQGCA NSWLADKFCD QACNVLSCGF DAGDCGQDHF
     HELYKVILLP NQTHYIIPKG ECLPYFSFAE VAKRGVEGAY SDNPIIRHAS IANKWKTIHL
     IMHSGMNATT IHFNLTFQNT NDEEFKMQIT VEVDTREGPK LNSTAQKGYE NLVSPITLLP
     EAEILFEDIP KEKRFPKFKR HDVNSTRRAQ EEVKIPLVNI SLLPKDAQLS LNTLDLQLEH
     GDITLKGYNL SKSALLRSFL MNSQHAKIKN QAIITDETND SLVAPQEKQV HKSILPNSLG
     VSERLQRLTF PAVSVKVNGH DQGQNPPLDL ETTARFRVET HTQKTIGGNV TKEKPPSLIV
     PLESQMTKEK KITGKEKENS RMEENAENHI GVTEVLLGRK LQHYTDSYLG FLPWEKKKYF
     QDLLDEEESL KTQLAYFTDS KNTGRQLKDT FADSLRYVNK ILNSKFGFTS RKVPAHMPHM
     IDRIVMQELQ DMFPEEFDKT SFHKVRHSED MQFAFSYFYY LMSAVQPLNI SQVFDEVDTD
     QSGVLSDREI RTLATRIHEL PLSLQDLTGL EHMLINCSKM LPADITQLNN IPPTQESYYD
     PNLPPVTKSL VTNCKPVTDK IHKAYKDKNK YRFEIMGEEE IAFKMIRTNV SHVVGQLDDI
     RKNPRKFVCL NDNIDHNHKD AQTVKAVLRD FYESMFPIPS QFELPREYRN RFLHMHELQE
     WRAYRDKLKF WTHCVLATLI MFTIFSFFAE QLIALKRKIF PRRRIHKEAS PNRIRV
//
